SCHEMBL6239468

SCHEMBL6239468

CCCS(=O)(=O)NC1CCCC1(O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.45
RORC P51449 1/20 0.41
ADAM17 P78536 3/20 0.41
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ELOVL6 Q9H5J4 1/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
MMP1 P03956 1/20 0.39
MMP13 P45452 1/20 0.39
KDM4E B2RXH2 1/20 0.39
KMT2A Q03164 1/20 0.39
ALOX5 P09917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6348256 0.97 AR (0.44) ARRORCADAM17RAB9ASMN1; SMN2
SCHEMBL6348528 0.88 PSEN1 (0.39) ADAM17SMN1; SMN2ELOVL6MMP1MMP13
SCHEMBL6240201 0.87 ADAM17 (0.38) ARRORCADAM17ELOVL6MMP1
SCHEMBL6345321 0.85 RORC (0.42) ARRORCADAM17RAB9ASMN1; SMN2
SCHEMBL6345959 0.85 RORC (0.42) ARRORCADAM17RAB9ASMN1; SMN2
SCHEMBL6239464 0.85 RORC (0.42) ARRORCADAM17RAB9ASMN1; SMN2
SCHEMBL6347109 0.85 ADAM17 (0.38) ARRORCADAM17ELOVL6MMP1
SCHEMBL6347711 0.85 PSEN1 (0.38) SMN1; SMN2ELOVL6MMP1MMP13ALOX5
SCHEMBL6345870 0.84 PSEN1 (0.41) SMN1; SMN2MMP13KMT2A
SCHEMBL6345812 0.84 RORC (0.46) ARRORCADAM17RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
EP-1395550-B1 CYCLOALKENYLSULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2005-06-29 EP disclosed
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US disclosed
US-20040157817-A1 Cycloalkenylsulfonamide derivatives CANTELL BUDDY EUGENE (US) 2004-08-12 US disclosed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed
EP-1395550-A1 CYCLOALKENYLSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-03-10 EP disclosed
WO-2002098847-A1 CYCLOALKENYLSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 AR 3446/4885RORC 2136/4885ADAM17 3636/4885
US-20040157817-A1 Cycloalkenylsulfonamide derivatives GRIN2B, GRIN2A, GRIN1 AR 3477/4885RORC 2238/4885ADAM17 3944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.